EvolusEOLS
About: Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.
Employees: 322
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
200% more call options, than puts
Call options by funds: $2.55M | Put options by funds: $851K
35% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 23
33% more capital invested
Capital invested by funds: $614M [Q2] → $815M (+$201M) [Q3]
28% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 43
5% more funds holding
Funds holding: 156 [Q2] → 164 (+8) [Q3]
10.59% less ownership
Funds ownership: 90.32% [Q2] → 79.72% (-10.59%) [Q3]
14% less funds holding in top 10
Funds holding in top 10: 7 [Q2] → 6 (-1) [Q3]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Douglas Tsao 41% 1-year accuracy 68 / 167 met price target | 149%upside $27 | Buy Reiterated | 7 Nov 2024 |
Financial journalist opinion
